Generic Name: pemigatinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Incyte

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Pemazyre is a kinase inhibitor approved for treatment of advanced or metastatic cholangiocarcinoma that carries a specific gene mutation.

General Info

Pemazyre is a kinase inhibitor that blocks fibroblast growth factor receptor (FGFR) types 1, 2 and 3. It is indicated for adults with cholangiocarcinoma with FGFR2 gene fusions or other genetic rearrangements.

The Phase II FIGHT-202 trial showed that Pemzyre shrank tumors in 36% of previously treated people with locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or genetic rearrangements. It was first approved in April 2020.


Dosing Info:

Pemazyre is taken as a tablet once daily for 14 days, followed by seven days off. It can be taken with or without food.

Side Effects

Common adverse events include abnormal phosphate levels, hair loss, diarrhea, constipation, nausea, vomiting, abdominal pain, decreased appetite, dysgeusia (abnormal taste sensations), fatigue, joint pain, back pain, nail problems, mouth sores, dry mouth, dry eyes and dry skin. Potential serious side effects may include eye problems and severely elevated phosphate levels (hyperphosphatemia). Pemazyre can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: April 20, 2020